 Immunotherapy
"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1983 | 0 | 1 | 1 | | 1985 | 1 | 2 | 3 | | 1986 | 1 | 0 | 1 | | 1988 | 0 | 1 | 1 | | 1989 | 2 | 2 | 4 | | 1990 | 1 | 1 | 2 | | 1991 | 4 | 0 | 4 | | 1992 | 1 | 1 | 2 | | 1994 | 0 | 1 | 1 | | 1995 | 1 | 1 | 2 | | 1996 | 1 | 0 | 1 | | 1998 | 0 | 3 | 3 | | 1999 | 2 | 1 | 3 | | 2000 | 3 | 2 | 5 | | 2001 | 2 | 5 | 7 | | 2002 | 2 | 3 | 5 | | 2003 | 2 | 5 | 7 | | 2004 | 5 | 8 | 13 | | 2005 | 3 | 2 | 5 | | 2006 | 5 | 2 | 7 | | 2007 | 4 | 1 | 5 | | 2008 | 7 | 7 | 14 | | 2009 | 3 | 1 | 4 | | 2010 | 7 | 5 | 12 | | 2011 | 5 | 5 | 10 | | 2012 | 8 | 7 | 15 | | 2013 | 8 | 11 | 19 | | 2014 | 6 | 8 | 14 | | 2015 | 11 | 15 | 26 | | 2016 | 22 | 2 | 24 | | 2017 | 25 | 4 | 29 | | 2018 | 28 | 14 | 42 | | 2019 | 32 | 20 | 52 | | 2020 | 22 | 22 | 44 | | 2021 | 23 | 15 | 38 | | 2022 | 1 | 9 | 10 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
DuBois SG, Macy ME, Henderson TO. High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-13.
-
Turchan WT, Pitroda SP, Weichselbaum RR. Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy. Neoplasia. 2022 May; 27:100782.
-
Chang JY, Verma V, Weichselbaum RR. Immunotherapy for the Neoadjuvant Management of Resectable Intrathoracic Cancers: Let's Not Forget Radiotherapy. JAMA Oncol. 2022 03 01; 8(3):333-334.
-
Ni K, Xu Z, Culbert A, Luo T, Guo N, Yang K, Pearson E, Preusser B, Wu T, La Riviere P, Weichselbaum RR, Spiotto MT, Lin W. Synergistic checkpoint-blockade and radiotherapy-radiodynamic therapy via an immunomodulatory nanoscale metal-organic framework. Nat Biomed Eng. 2022 02; 6(2):144-156.
-
Meric-Bernstam F, Sweis RF, Hodi FS, Messersmith WA, Andtbacka RHI, Ingham M, Lewis N, Chen X, Pelletier M, Chen X, Wu J, McWhirter SM, Müller T, Nair N, Luke JJ. Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2022 02 15; 28(4):677-688.
-
Ghaffari Laleh N, Loeffler CML, Grajek J, Stanková K, Pearson AT, Muti HS, Trautwein C, Enderling H, Poleszczuk J, Kather JN. Classical mathematical models for prediction of response to chemotherapy and immunotherapy. PLoS Comput Biol. 2022 02; 18(2):e1009822.
-
Augustin RC, Leone RD, Naing A, Fong L, Bao R, Luke JJ. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. J Immunother Cancer. 2022 02; 10(2).
-
Minor DR, Kim KB, Tong RT, Wu MC, Kashani-Sabet M, Orloff M, Eschelman DJ, Gonsalves CF, Adamo RD, Anne PR, Luke JJ, Char D, Sato T. A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma. Cancer Biother Radiopharm. 2022 Feb; 37(1):11-16.
-
Donington J, Schumacher L, Yanagawa J. Surgical Issues for Operable Early-Stage Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 02 20; 40(6):530-538.
-
Matsuzaki J, Lele S, Odunsi K, Tsuji T. Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer. Oncoimmunology. 2022; 11(1):2020983.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|